159 related articles for article (PubMed ID: 34069121)
1. Circulating Forms of Urokinase-Type Plasminogen Activator Receptor in Plasma Can Predict Recurrence and Survival in Patients with Urothelial Carcinoma of the Bladder.
Dohn LH; Thind P; Salling L; Lindberg H; Oersted S; Christensen IJ; Laerum OD; Illemann M; von der Maase H; Høyer-Hansen G; Pappot H
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34069121
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Dohn LH; Illemann M; Høyer-Hansen G; Christensen IJ; Hostmark J; Litlekalsoy J; von der Maase H; Pappot H; Laerum OD
Urol Oncol; 2015 Apr; 33(4):165.e15-24. PubMed ID: 25575713
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
Janisch F; D'Andrea D; Iwata T; Kimura S; Abufaraj M; Enikeev D; Glybochko PV; Karakiewicz PI; Nyirady P; Fajkovic H; Haitel A; Seebacher V; Rink M; Shariat SF
Urol Oncol; 2020 May; 38(5):423-432. PubMed ID: 32209281
[TBL] [Abstract][Full Text] [Related]
4. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
[TBL] [Abstract][Full Text] [Related]
5. uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Dohn LH; Pappot H; Iversen BR; Illemann M; Høyer-Hansen G; Christensen IJ; Thind P; Salling L; von der Maase H; Laerum OD
PLoS One; 2015; 10(8):e0135824. PubMed ID: 26292086
[TBL] [Abstract][Full Text] [Related]
6. Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer.
Almasi CE; Brasso K; Iversen P; Pappot H; Høyer-Hansen G; Danø K; Christensen IJ
Prostate; 2011 Jun; 71(8):899-907. PubMed ID: 21456072
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients.
Grunnet M; Christensen IJ; Lassen U; Jensen LH; Lydolph M; Lund IK; Thurison T; Høyer-Hansen G; Mau-Sørensen M
Clin Biochem; 2014 May; 47(7-8):599-604. PubMed ID: 24530340
[TBL] [Abstract][Full Text] [Related]
8. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer.
Almasi CE; Høyer-Hansen G; Christensen IJ; Pappot H
APMIS; 2009 Oct; 117(10):755-61. PubMed ID: 19775344
[TBL] [Abstract][Full Text] [Related]
10. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
11. Circulating intact and cleaved forms of the urokinase-type plasminogen activator receptor: biological variation, reference intervals and clinical useful cut-points.
Thurison T; Christensen IJ; Lund IK; Nielsen HJ; Høyer-Hansen G
Clin Chim Acta; 2015 Jan; 439():84-90. PubMed ID: 25305537
[TBL] [Abstract][Full Text] [Related]
12. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.
Abufaraj M; Kimura S; Haitel A; Iwata T; Isleem U; D'Andrea D; Soria F; Mori K; Rink M; Bensalah K; Rouprêt M; Margulis V; Briganti A; Karakiewicz PI; Shariat SF
Urol Oncol; 2020 Aug; 38(8):685.e17-685.e25. PubMed ID: 32381392
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
[TBL] [Abstract][Full Text] [Related]
15. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
16. Urokinase receptor variants in tissue and body fluids.
Høyer-Hansen G; Lund IK
Adv Clin Chem; 2007; 44():65-102. PubMed ID: 17682340
[TBL] [Abstract][Full Text] [Related]
17. Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis.
Almasi CE; Christensen IJ; Høyer-Hansen G; Danø K; Pappot H; Dienemann H; Muley T
Lung Cancer; 2011 Dec; 74(3):510-5. PubMed ID: 21640427
[TBL] [Abstract][Full Text] [Related]
18. Urokinase receptor cleavage correlates with tumor volume in a transgenic mouse model of breast cancer.
Thurison T; Almholt K; Gårdsvoll H; Ploug M; Høyer-Hansen G; Lund IK
Mol Carcinog; 2016 May; 55(5):717-31. PubMed ID: 25809119
[TBL] [Abstract][Full Text] [Related]
19. Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab.
Tarpgaard LS; Christensen IJ; Høyer-Hansen G; Lund IK; Guren TK; Glimelius B; Sorbye H; Tveit KM; Nielsen HJ; Moreira JM; Pfeiffer P; Brünner N
Int J Cancer; 2015 Nov; 137(10):2470-7. PubMed ID: 25664394
[TBL] [Abstract][Full Text] [Related]
20. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
